Carbonic anhydrase inhibitors: CA IX selective inhibitors incorporating aromatic or heterocyclic sulfonamide

Abstract

A new antitumour therapy approach, via selective inhibition of tumour associated carbonic anhydrase isozyme IX with aromatic/heterocyclic sulfonamide and positively charged related derivatives, is provided. A series of compounds with nanomolar inhibitory activities are claimed, which constitute interesting leads for developing novel antitumour therapies.